NasdaqGM:ANIPPharmaceuticals
How Strong Q2 Results and Raised Guidance at ANI Pharmaceuticals (ANIP) Have Changed Its Investment Story
ANI Pharmaceuticals recently reported its second quarter 2025 results, showing sales of US$211.37 million and a swing to net income of US$8.55 million, while also raising its full-year earnings guidance to US$818 million–US$843 million.
This performance was highlighted by significant growth in the Rare Disease and Generics segments, prompting analysts to update their coverage to reflect the stronger outlook.
We'll examine how the raised full-year financial guidance reinforces ANI...